Overview

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

Status:
Completed
Trial end date:
2020-09-07
Target enrollment:
0
Participant gender:
All
Summary
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:

- Healthy Volunteers who are ≥19 years old

- Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 and

Exclusion Criteria:

- Clinically significant Medical History

- In the case of women, pregnant(Urine-HCG positive) or lactating women